Stevanato Group S.p.A. (NYSE:STVN) Stock Holdings Trimmed by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC decreased its position in Stevanato Group S.p.A. (NYSE:STVN) by 48.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,189 shares of the company’s stock after selling 1,119 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Stevanato Group were worth $32,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Raymond James & Associates lifted its holdings in Stevanato Group by 0.9% in the third quarter. Raymond James & Associates now owns 197,316 shares of the company’s stock worth $5,864,000 after acquiring an additional 1,806 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stevanato Group during the 3rd quarter valued at approximately $255,000. Calamos Wealth Management LLC bought a new position in Stevanato Group during the 3rd quarter worth $1,456,000. Conestoga Capital Advisors LLC increased its position in Stevanato Group by 19.7% in the third quarter. Conestoga Capital Advisors LLC now owns 4,534,088 shares of the company’s stock worth $134,753,000 after buying an additional 746,136 shares during the period. Finally, Fifth Third Bancorp lifted its stake in Stevanato Group by 70.1% in the third quarter. Fifth Third Bancorp now owns 2,473 shares of the company’s stock valued at $73,000 after buying an additional 1,019 shares during the last quarter.

Stevanato Group Price Performance

Shares of NYSE STVN traded down €0.36 ($0.39) during mid-day trading on Friday, reaching €26.45 ($28.44). 277,600 shares of the company traded hands, compared to its average volume of 336,883. The firm has a market cap of $7.82 billion, a PE ratio of 44.83, a price-to-earnings-growth ratio of 2.96 and a beta of 0.76. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.50 and a quick ratio of 1.06. Stevanato Group S.p.A. has a fifty-two week low of €23.00 ($24.73) and a fifty-two week high of €36.30 ($39.03). The stock has a fifty day simple moving average of €29.63 and a 200-day simple moving average of €29.20.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Thursday, March 7th. The company reported €0.18 ($0.19) EPS for the quarter, missing analysts’ consensus estimates of €0.19 ($0.20) by (€0.01) (($0.01)). The firm had revenue of €320.60 million during the quarter, compared to the consensus estimate of €326.85 million. Stevanato Group had a return on equity of 14.31% and a net margin of 13.43%. The firm’s quarterly revenue was up 9.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.19 EPS. Equities research analysts anticipate that Stevanato Group S.p.A. will post 0.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

STVN has been the topic of a number of analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $30.00 price objective on shares of Stevanato Group in a report on Monday, April 22nd. BNP Paribas started coverage on Stevanato Group in a report on Monday, April 22nd. They set an “outperform” rating on the stock. Finally, Stephens reissued an “overweight” rating and issued a $38.00 price objective on shares of Stevanato Group in a report on Monday, March 25th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of €33.63 ($36.16).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.